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S230 Oral Presentationsdisease (score 3, 4 or 5). Type of donor: Related: 8pts (siblings: 5pts
and other related:3pts), Unrelated: 28pts. Source of stem cells: bone
marrow (BM): 12pts and umbilical cord blood (UCB):24pts (com-
patibility 6 / 6: 2pts, 5 / 6: 16pts, 4 / 6: 6pts). Conditioning: Cyclo-
phosphamide120-200mg/kg + Oral Busulfan16-20mg/kg +/- rATG.
Most pts received cyclosporine andmethotrexate as GVHDprophy-
laxis.
Results: 28pts is alive and well between 6 months and 17 ys after
HSCT (M:4,5ys) with an overall survival(OS) of 80,3% at 5ys.
35pts survived more than 28 days and were evaluable for engraft-
ment. Three pts had no engraftment (all received UCB).One pt
died onD+34 with pulmonary aspergillosis and the other two under-
went a 2nd UCBT. One is alive and well 7 years after transplant.
Nine of 32 evaluable pts developed an acute-GVHD, grades II-IV
(grade III-IV: 2pts). Eight of 31 evaluable pts developed C-GVHD
(extensive in 3pts). There was no significant difference in OS in
the univariate or multivariate analysis in relation to age less than
or greater than 5 years (76% vs. 82%), type of donor, related or un-
related (87.5% vs. 75%), source of stem cells, bone marrow or cord
blood (91.7% vs. 70,8%), presence or absence of acute-GVHD (78%
vs 92%); or Chronic GVHD (75% vs 91%). Eight pts died between
21 to 1832 days post HSCT (M: 137 days), most deaths occurred
during the first year of transplant (6pts) and were related to viral in-
fections (4pts), fungal (1pt) and GVHD associated with bacterial in-
fections (3pts). The cumulative incidence of TRM at 100 days was
8% and at 1 year was of 17%. Chemotherapy was well tolerated,
but reactivation/acquisition of viral infections (mainly RSV) during
the period of neutropenia contributed to the early death in some pts.
Conclusions: Despite the small number of pts this experince shows
an excellent survival for pts transplanted for WAS. Infections com-
plications (viral or fungal) are frequent and must be detected quickly
and treated aggressively.74
EFFECTS OF BODY MASS INDEX (BMI) IN CHILDREN UNDERGOING AL-
LOGENEIC BONEMARROWTRANSPLANT (BMT) FOR HEMATOLOGIC MA-
LIGNANCIES
Aplenc, R.1, Pasquini, M.C.2, Zhang,M.-J.2, Zhu, X.2, McCarthy, P.L.3,
Ho, V.T.4, Cooke, K.R.5, Sung, L.6, Bunin, N.J.1 1Children’s Hospital of
Philadelphia; 2CIBMTR, Medical College of Wisconsin; 3Roswell Park
Cancer Institute; 4Dana-Farber Cancer Institute; 5University Hospitals
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The rising incidence of pediatric obesity may significantly impact
BMT outcomes for malignant diseases, as has been demonstrated in
increased mortality in children undergoing BMT for aplastic ane-
mia. Obesity may influence chemotherapy dosing and transplant re-
lated mortality (TRM). We analyzed 3,687 children ages 2-18, who
received BMT for treatment of hematologic malignancies using ei-
ther busulfan/cyclophosphamide (BuCy, N 5 1,196) or Cy/total
body irradiation-based (CyTBI, N 5 2,495) conditioning, between
1990 and 2007. Recipients were classified according to age-adjusted
BMI percentiles as underweight (\5% [UW], n5 282), at risk of un-
derweight (6-25% [RUW], n 5 509), normal (26-75%,[NW] n 5
1469), at risk of overweight (76-95% [ROW], n 5 987) and obese
(.95%, [OB] n 5 444). Total doses of chemotherapy administered
to patients in the ROW and OB groups were divided by actual and
ideal body weight to estimate dose adjustment practices. Median
age (10-13 y) and race were similar in all groups; OB group had
higher number of patients with acute lymphocytic leukemia (58%),
with early disease (52%), unrelated donor recipients (56%) and
from a U.S. center (61%). The table below summarizes adjusted
probabilities according to BMI groups.Multivariate analysis demon-
strated a higher TRM in the OB group (RR 1.32, p 5 0.0075) com-
pared to NW. Conversely, patients in the OB group had decreased
risk of relapse (RR 0.72, p 5 0.0037) compared to NW. There was
no significant impact of UW and RUW compared to NW in any
outcomes, and no differences in relapse-free and overall survival ac-
cording to BMI groups. Chemotherapy adjustment assessment dem-
onstrated that among 1,061 patients with available dose information,
171 (16%) had probable dose adjustment for conditioning. Obesity
was associated with higher TRM and lower relapse in children
with hematologic malignancies, likely related to higher intensity
conditioning, as doses were most often calculated based on actualweight. Additionally, patients with low BMI experienced similar out-
comes compared to patients with NW.
Table.
Outcomes UW RUW NW ROW OB
@ 3 years (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) p-valueN 282 509 1467 986 443
TRM 18 (13-22) 19 (16-22) 21 (18-22) 22 (20-25) 28 (24-32) 0.0034
Relapse 33 (28-39) 33 (29-37) 29 (26-31) 25 (23-28) 21 (17-25) <0.0001
RFS 48 (42-54) 48 (44-53) 50 (48-53) 52 (49-56) 51 (47-56) 0.54
OS 55 (49-61) 57 (52-61) 58 (56-61) 58 (55-61) 56 (52-61) 0.81Abbreviations: CI, confidence interval; NW, normal weight; OB, obese;
OS, Overall Survival; RFS, relapse free survival; ROW, risk of over-
weight; RUW, risk of underweight; UW, underweight
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SINGLE CENTER EXPERIENCE OF THIOTEPA, TREOSULPHAN & FLUDAR-
ABINE BASED REGIMEN IN THALASSEMIA MAJOR
Choudhary, D.1, Katewa, S.2, Kharya, G.1, Anjan, M.1, Setia, R.1 1BLK
Super Speciality Hospital, New Delhi, Delhi, India; 2Hospital for Sick
Children, Toronto, ON, Canada
The only curative treatment for Thalassemia major (TM) is allo-
genic bone marrow transplantation. The most commonly used con-
ditioning regimen is Busulphan, Cyclophosphamide and Anti
thymocyte globulin. This has high regimen related toxicities
(RRT). To minimize RRT, especially in high risk TM we studied
new conditioning regimen in prospectivemanner. Between February
2010 - September 2011, seventeen children with b-Thalassemia ma-
jor underwent Allogenic Bone Marrow Transplant at BLK Super
Speciality Hospital. The median age was 12 years. (Range 2-16 yrs.).
There were nine males & eight females, four patients belonged to
Pesaro class II and 13 were class III. All patients received condition-
ing with Thiotepa 8 mg/kg on D -6, Treosulphan 14 gm/m2/day
from D-5 to D-3 & Fludarabine 40 mg/m2/day from D-5 to D -2.
Sixteen children were transplanted with bone marrow graft from
HLA identical siblings (6/6 antigen) and one patient received bone
marrow graft from mother (5/6 antigen). Mean cell doses given
were: 6.36 106 cells /kg BW for CD34+ cells (Range 2.06 – 14.02
 106/kg) and 7.84  10 8/kg /BW for mononuclear cells (Range
2.9- 17.5 108/kg). Two patients had ABO major mismatch, 4 had
minor mismatch and 1 had bidirectional mismatch. Cyclosporine
& Methotrexate was used as GVHD prophylaxis. No patient devel-
oped grade III - IVGVHD.None of them requiredTPNor parental
analgesia. Sixteen out of seventeen patients achieved donor engraft-
ment.Median neutrophil engraftment was achieved onD+15 (Range
11 – 17 day) and median platelet engraftment was achieved on D+21
(Range 9 to 34 days). One patient developed grade II gut GVHD.
One patient expired on D+6 due to neutropenic enterocolitis, sepsis
and intracranial hemorrhage.
Median follow-up period was 12 months (Range 1 -20 mo). Till
last follow up, all the patients who achieved engraftment are alive
and transfusion independent.
Conclusion: Thiotepa, Treosulphan & Fludarabine based regimen
has acceptable toxicities with stable donor engraftment.
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UNRELATED CORD BLOOD TRANSPLANT (UCBT) IS ASSOCIATED LOW
RATES OF LONGTERM, PERSISTENT GRAFT VERSUS HOST DISEASE
(GVHD)
Craddock, J.A., Alsultan, A., Quinones, R.R., Keating, A., Hild, E.,
Benkhalil, N., Law, D., Peltz, A., Nuechterlein, B., Drake, K.,
Smolik, S., Giller, R.H. Childrens Hospital Colorado/University of Colo-
rado School of Medicine, Aurora, CO
Reduced rates of acute and chronic GVHD make unrelated cord
blood an attractive stem cell source. Adult marrow and PBSC from
unrelated donors are associated with higher rates of GVHD, persis-
tence or progression of GVHDmanifestations, need for chronic im-
munosuppressive therapies, reduced quality of life, infection, organ
toxicities, and decreased overall survival (OS). In contrast, recent
analyses from our center and others have indicated that GVHD
following UCBT does not adversely impact OS (BMT 2011,
46:668-675). To better understand the longterm outcomes of
